Cosentyx (secukinumab) - Novartis
Cosentyx: Regulatory submission in US for pediatric psoriasis in 2020 (Novartis) - Jan 29, 2020 - Q4 and FY 2019 Results: Regulatory submission for psoriatic arthritis (head to head) in 2020; Regulatory submission for ankylosing spondylitis in 2024 or later 
Regulatory • sBLA
https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.pdf
 
Jan 29, 2020
 
 
8a17d682-3f07-43f6-a7cf-7146be79c50d.jpg